Research Study

A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Principal Investigator 
Eric M. Yoshida

Overview

Body Locations and Systems 
Liver Diseases
ClinicalTrials.gov# 
NCT02548351
Status 
Recruiting
Study Start/End 
May 25, 2016 to Apr 25, 2022
Locations 
Diamond Health Care Centre, Vancouver General Hospital
Name/Title 
Kirby Lau, Research Coordinator
Phone 
604-875-5223
Email Address 
kirby.lau@vch.ca
Purpose of Study 

The primary objectives of this study are to evaluate the effect of Obeticholic Acid treatment compared to placebo on 1) histological improvement and 2) liver-related clinical outcomes in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH) with liver fibrosis.

Eligibility 

Visit ClinicalTrials.gov for more information.  

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific clinical research trials only. If you have specific questions which require clinical expertise, please call your primary care physician.